News
Small Pharma begins phase 1 mental health therapy trial
Small Pharma – a company focused on psychedelic-assisted therapies for mental health conditions –has confirmed that a first subject has been dosed in its phase 1 study evaluating SPL028.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Small Pharma – a company focused on psychedelic-assisted therapies for mental health conditions –has confirmed that a first subject has been dosed in its phase 1 study evaluating SPL028.